E.E. Geduld’s TherapeuticsMD TXMD Stock Holding History

E.E. Geduld’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$289K	Buy	1,000 +800	+400%	+$248K	0.16%	54
2016 Q3	$68K	Buy	+200	New	+$73K	0.07%	139
2016 Q2	–	Sell	-200	Closed	-$64K	–	183
2016 Q1	$64K	Buy	+200	New	+$68.2K	0.09%	117
2015 Q4	–	Sell	-250	Closed	-$73K	–	217
2015 Q3	$73K	Sell	250 -350	-58%	-$124K	0.07%	142
2015 Q2	$236K	Buy	+600	New	+$212K	0.15%	159

Other funds holding TXMD

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

E.E. Geduld's TXMD Position: Q4 2016 in Review

E.E. Geduld increased its TherapeuticsMD (TXMD) stake by 400% in Q4 2016, buying an estimated $248K and bringing the position to 1,000 shares worth $289K. The position accounts for 0.16% of the portfolio, ranked #54.

E.E. Geduld first reported a position in TXMD in Q2 2015 and has held it in 5 quarters since. 146 funds tracked by Wall St. Rank hold TXMD as of Q4 2016.

E.E. Geduld held 1,000 shares of TherapeuticsMD worth $289K as of Q4 2016.
E.E. Geduld bought 800 TherapeuticsMD shares in Q4 2016, an estimated $248K.
TherapeuticsMD made up 0.16% of E.E. Geduld's portfolio in Q4 2016, its #54 holding.
E.E. Geduld first reported a position in TherapeuticsMD in Q2 2015 and has held it in 5 quarters since.
146 funds tracked by Wall St. Rank held TherapeuticsMD as of Q4 2016.

Based on E.E. Geduld's 13F filing for Q4 2016, filed 8 Feb 2017.